DE-BIOCORP
1.10.2020 07:32:15 CEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS® ), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Surges in Oulu as European Capital of Culture Year Drives Record Visitor Numbers and Major Exhibitions5.5.2026 14:23:00 CEST | Press release
The European Capital of Culture year has boosted tourism and cultural attendance in Oulu, with strong growth in overnight stays, record-breaking visitor numbers and major exhibitions attracting local and international audiences. The year has started strongly in Oulu, Finland, with tourism and cultural attendance rising across sectors. In January–February, total overnight stays increased by more than 20%, while February alone saw a 32% increase, reaching 78,400 stays. International tourism grew by over 40%. At the same time, the opening festival in January attracted around 250,000 visits, highlighting strong interest among both residents and visitors and signalling a promising year for the city’s tourism sector. “The start of the year has clearly shown the power of culture in strengthening tourism and regional vitality,” says Oulu2026 Programme Director Samu Forsblom. “With hundreds of cultural operators across all 39 municipalities involved, this is a unique year to visit our region in
Fleet Launch Customer NetJets Takes Delivery of First Three Cessna Citation Ascend Midsize Business Jets5.5.2026 14:00:00 CEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, achieved a major milestone as the first three Cessna Citation Ascend business jets were delivered to fleet launch customer NetJets. NetJets, which operates the world's largest, most diverse private jet fleet, is the first private fleet operator to take delivery and begin operations with the Cessna Citation Ascend. Setting new standards in performance, comfort and operational efficiency for the midsize business jet market, the Citation Ascend builds on the longstanding relationship between Textron Aviation and NetJets by offering owners a seamless progression of advanced aircraft designed to deliver exceptional reliability, efficiency and luxury. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505495566/en/ Fleet launch customer NetJets takes delivery of first three Cessna Citation Ascend midsize business jets. (Photo Credit: Textron Aviation) “The Citation Ascend re
Bracco Launches BubbleGen™ Early Access Program for Microbubble-Based Cell Selection and Activation at ISCT5.5.2026 14:00:00 CEST | Press release
Bracco's new BubbleGen technology streamlines cell therapy manufacturing for one-step cell separation and activation with no magnetic residualsBubbleGen microbubbles can target specific cell subtypes, including rare populationsDemos available for BubbleGen at ISCT, Booth #2711 Bracco Imaging,a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, unveiled its Early Access Program today to enable cell therapy developers to evaluate the company’s new BubbleGen™ technology for cell therapy. Bracco’s team will be showcasing BubbleGen, which is designed to support a range of streamlined cell therapy manufacturing processes, at the International Society for Cell & Gene Therapy (ISCT) 2026 conference held this week in Dublin, Ireland. Through the BubbleGen evaluation kit, academic and industry researchers can explore a new approach to cell separation. The technology uses buoyant microbubbles to isolate specific cells, offering an alternative t
ATLAS Infrastructure Cornerstones United Utilities £800m Equity Placement5.5.2026 13:12:00 CEST | Press release
ATLAS participated as an exclusive Cornerstone investor in United Utilities’ equity placement, expanding its existing investment to establish a significant minority shareholding.ATLAS was pleased with the strong support for the transaction from other long-term shareholders signalling broad support for United Utilities’ investment and growth strategy.United Utilities’ fully funded capital investment program underpins a strong multi-year growth trajectory1. ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing capital on behalf of its funds and long-term institutional clients. ATLAS has been an investor in UU since 2019 and, following the recent equity placement, ATLAS’s actively managed accounts hold a ~6.6% voting and economic interest in United Utilities plc (“UU”). ATLAS recognises the positive new direction established for the UK water sector and welcomes the opportunity to support UU management’s investment plan which will deliver the critica
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent5.5.2026 12:37:00 CEST | Press release
Highly experienced partners bringing 25+ years of leadership across top-tier life-sciences investment fund, pharma and Biopharma companies, driving accelerated portfolio developmentWith leadership experienceat Blackstone Life Sciences (Deputy Chief Operating Officer), Biogen, (NASDAQ: BIIB), and public and private Biopharma companies (including Kymera Therapeutics (NASDAQ: KYMR)and Cygnal Therapeutics), Elaine Caughey will support portfolio companies in strengthening operational execution, defining robust market access pathways, and enhancing their strategic value through business development support, including partnerships and acquisition transactions. She will also draw on her knowledge of the investment ecosystem to strengthen relationships with investors for both Jeito funds and its portfolio companiesSarah brings deep strategic expertise from senior roles at leading Biopharma investment firms - including as Partner, Marketing and Talent at Abingworth and as Chief Talent Officer at
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom